Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable

Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME’s Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.

Gene editing exposure is recommended for biotech portfolios; PRME offers high-risk, technology-driven upside, while BEAM provides nearer-term commercial catalysts and stronger funding.

The stock of Cambridge, Massachusetts-based biotech Prime Medicine, Inc. ( PRME ) rose in value by >15% in trading yesterday, to >$4.6 per share (market cap valuation of ~$835m), as it reported.